Patents by Inventor Joseph P. Yevich

Joseph P. Yevich has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 5434154
    Abstract: A series of novel alkoxypyridin-4-yl and alkoxypyrimidin-4-yl derivatives of indol-3-ylalkylpiperazines of Formula I are intended to be useful agents ##STR1## for alleviation of vascular headache on the basis of their potent affinity and agonist activity at 5-HT1D binding sites.
    Type: Grant
    Filed: April 26, 1994
    Date of Patent: July 18, 1995
    Assignee: Bristol-Myers Squibb Company
    Inventors: David W. Smith, Joseph P. Yevich, Andrew Williams, Edward H. Ruediger, Keith D. Combrink, Bradley C. Pearce
  • Patent number: 5382592
    Abstract: A series of serotonergic 5-cyclobutenedionylamino-substituted tryptamine derivatives of Formula I is disclosed for use in the alleviation of vascular headaches. ##STR1## The formula I substituents, as further defined in the specification, are: R.sup.1 is hydrogen, halogen, and alkyl; R.sup.2 and R.sup.3 can be hydrogen or alkyl; R.sup.4 is hydrogen, alkyl, acyl or alkylsulfonyl; m is 0 to 3 and n is 1 to 5; and X is amino, alkoxy, hydrogen, alkyl, aryl or alkylaryl.
    Type: Grant
    Filed: September 16, 1993
    Date of Patent: January 17, 1995
    Assignee: Bristol-Myers Squibb Company
    Inventors: Jonas A. Gylys, Edward H. Ruediger, David W. Smith, Carola Solomon, Joseph P. Yevich
  • Patent number: 5338738
    Abstract: A series of acyclic amide derivatives of pyrimidinylpiperazines of Formula I ##STR1## wherein R.sup.1 is alkyl, phenalkyl, phenyl-hydroxyalkyl, phenyl and pyridinyl; R.sup.2 and R.sup.3 are hydrogen and alkyl; and R.sup.4 is hydrogen, halogen, and trifluoromethyl.Compounds of the invention can be incorporated into pharmaceutical compositions for use in enhancing cerebral function. The compounds are envisioned as being useful in restoration of cerebral function in degenerative disorders; in amnesia reversal; and in improvement of memory and learning processes.
    Type: Grant
    Filed: April 19, 1993
    Date of Patent: August 16, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: Ronald J. Matson, Joseph P. Yevich
  • Patent number: 5300506
    Abstract: A series of novel indol-3-ylalkyl derivatives of alkoxypyrimidinylpiperazines are disclosed as Formula I. ##STR1## These compounds are intended to be useful agents for alleviation of vascular headache on the basis of their potent affinity and agonist activity at 5-HT1D binding sites.
    Type: Grant
    Filed: October 13, 1992
    Date of Patent: April 5, 1994
    Assignee: Bristol-Myers Squibb Company
    Inventors: David W. Smith, Frank D. Yocca, Joseph P. Yevich, Ronald J. Mattson, Andrew Williams, Edward H. Ruediger
  • Patent number: 5077293
    Abstract: Certain 1-indolylalkyl-4-(alkoxypyrimidinyl)piperazines of Formula I are useful antidepressant agents. The ##STR1## substituents R.sup.1, R.sup.2 and R.sup.5 are hydrogen or lower alkyl; R.sup.3 and R.sup.4 are hydrogen, alkyl, alkoxy, alkythio, carboxamido, halo, or trifluoromethyl; R.sup.6 is alkoxy; and n is the integer 2 or 3.
    Type: Grant
    Filed: June 29, 1990
    Date of Patent: December 31, 1991
    Assignee: Bristol-Myers Squibb Co.
    Inventors: David W. Smith, Frank D. Yocca, Joseph P. Yevich, Ronald J. Mattson
  • Patent number: 4994460
    Abstract: A series of 5-halopyrimidin-2-ylpiperazinylalkyl derivatives having useful anti-ischemic properties for treatment and prevention of dirorders resulting from brain and/or spinal cord anoxia.
    Type: Grant
    Filed: March 30, 1990
    Date of Patent: February 19, 1991
    Assignee: Bristol-Myers Squibb Co.
    Inventors: Pierre Dextraze, Joseph P. Yevich
  • Patent number: 4954502
    Abstract: A series of 1,4-disubstituted piperazine derivatives comprised of indol-3-ylalkyl and substituted pyridin-2-yl substituent groups. These compounds are useful as antidepressant agents.
    Type: Grant
    Filed: April 14, 1989
    Date of Patent: September 4, 1990
    Assignee: Bristol-Myers Squibb Company
    Inventors: David W. Smith, Frank D. Yocca, Joseph P. Yevich, Ronald J. Mattson
  • Patent number: 4826843
    Abstract: A series of diazinylpiperidine compounds of Formula I ##STR1## wherein X is an ethylene chain or a 1,2-benzo ring; Y is carbonyl or methylene; R.sup.1 is hydrogen or lower alkyl; and Z is an R.sup.2, R.sup.3 -disubstituted diazinyl ring selected from pyridazine, pyrimidine, and pyrazine ring systems. Pharmacologic and neuroanatomical testing demonstrates that compounds of the series act to enhance cerebral function in mammals, particularly when there is a deficit in normal cerebral functioning. Specific pharmacologic test results indicate that compounds of Formula I possess cognition and memory enhancing activity.
    Type: Grant
    Filed: August 28, 1987
    Date of Patent: May 2, 1989
    Assignee: Bristol-Myers
    Inventors: Ronald J. Mattson, Joseph P. Yevich, Michael S. Eison
  • Patent number: 4784998
    Abstract: Psychotropic 1,3,4-oxadiazole compounds and their use as tranquilizers, analgesics and antidepressants.
    Type: Grant
    Filed: April 6, 1987
    Date of Patent: November 15, 1988
    Assignee: Bristol-Myers Company
    Inventor: Joseph P. Yevich
  • Patent number: 4757073
    Abstract: Disubstituted N,N-piperazinyl derivatives are disclosed wherein one substituent is a substituted pyridin-2-yl ring and the second substituent is a butylene chain attached to cyclic imide heterocycles such as azaspiro[4.5]decanedione, dialkylglutarimide, thiazolidinedione, spirocyclopentylthiazolidinedione, or morpholine-2,6-dione. The compounds have psychotropic properties and 2-[4-[4-(2,4-dioxo-1-thia-3-azaspiro[4.5]nonane-3-yl)butyl]-1-piperazinyl] -pyridine-3-carboxaldehyde is a typical embodiment having selective antipsychotic activity.
    Type: Grant
    Filed: September 30, 1986
    Date of Patent: July 12, 1988
    Assignee: Bristol-Myers Company
    Inventors: James S. New, Walter G. Lobeck, Jr., Joseph P. Yevich
  • Patent number: 4677104
    Abstract: Disubstituted 1,4-piperazinyl derivatives are disclosed wherein one substituent is a bicyclic fused-ring furo-, pyrrolo-, cyclopentadieno-, or thieno-pyridine heterocyclic system and the second substituent is an alkylene chain attached to cyclic imide heterocycles, such as azaspiro[4.5]decanediones, dialkylglutarimides, thiazolidinediones, succinimides, and morpholine-2,6-diones; or a benzylic carbinol moiety. These compounds have potent antipsychotic and serotonin antagonist activities. 4-[4-[4-(4-Furo[3,2-c]pyridinyl)-1-piperazinyl]butyl]-3,5-morpholinedione is an example of a typical embodiment having selective antipsychotic activity.
    Type: Grant
    Filed: July 16, 1986
    Date of Patent: June 30, 1987
    Assignee: Bristol-Myers Company
    Inventors: James S. New, Joseph P. Yevich
  • Patent number: 4668687
    Abstract: A series of nootropic compounds of the following formula: ##STR1## and its pharmaceutically acceptable acid addition salts, wherein: R.sup.2 is hydrogen, lower alkyl, aryl which is optimally substituted, or hetaryl;R.sup.7 is hydrogen or is combined with R.sup.9 as a fused benzo-ring;R.sup.8 is hydrogen or lower alkyl; andR.sup.9 is lower alkyl, or R.sup.9 can be combined with R.sup.8 to give a 2-pyrrolidinone, a phthalimide, or isoindolone ring system.Pharmacological testing demonstrates that the series possesses cognition and memory enhancing actions and/or mild CNS simulation.
    Type: Grant
    Filed: November 19, 1985
    Date of Patent: May 26, 1987
    Assignee: Bristol-Myers Company
    Inventors: Joseph P. Yevich, Ronald J. Mattson
  • Patent number: 4656173
    Abstract: 8-[4-[4-(1-Oxo-1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5 ]decane-7,9-dione is an antipsychotic agent having reduced side effect liability.
    Type: Grant
    Filed: April 24, 1985
    Date of Patent: April 7, 1987
    Assignee: Bristol-Myers Company
    Inventors: Joseph P. Yevich, Walter G. Lobeck, Jr.
  • Patent number: 4619930
    Abstract: Disubstituted N,N-piperazinyl derivatives are disclosed wherein one substituent is a substituted pyridin-2-yl ring and the second substituent is a butylene chain attached to cyclic imide heterocycles such as azaspiro[4.5]decanedione, dialkylglutarimide, thiazolidinedione, spirocyclopentylthiazolidinedione, or morpholine-2,6-dione. The compounds have psychotropic properties and 2-[4-[4-(2,4-dioxo-1-thia-3-azaspiro[4.5]nonane-3-yl)butyl]-1-piperazinyl] pyridine-3-carboxaldehyde is a typical embodiment having selective antipsychotic activity.
    Type: Grant
    Filed: January 16, 1985
    Date of Patent: October 28, 1986
    Assignee: Bristol-Myers Company
    Inventors: James S. New, Walter G. Lobeck, Jr., Joseph P. Yevich
  • Patent number: 4613600
    Abstract: 2-[3-[4-(3-Halophenyl)-1-piperazinyl]propyl]-5-(1-hydroxyethyl)-2,4-dihydro -[4-phenoxyalkyl-3H-1,2,4-triazol-3-ones and closely related compounds are psychotropic agents having promise as antidepressants by virtue of their receptor site binding affinity profiles and animal pharmacology.
    Type: Grant
    Filed: September 30, 1983
    Date of Patent: September 23, 1986
    Assignee: Mead Johnson & Company
    Inventors: Richard E. Gammans, David W. Smith, Joseph P. Yevich
  • Patent number: 4605655
    Abstract: Disubstituted N,N-piperazinyl derivatives are disclosed wherein one substituent is a pyrimidin-2-yl ring and the other is a 4 carbon chain attached to a p-fluorophenyl ring at the terminal carbon. The terminal carbon of this butylene chain is also bonded to an oxygen atom as part of a carbonyl, carbinol, or ketal functionality. These compounds possess psychotropic properties, particularly atypical antipsychotic activity of good duration. By virtue of pre-clinical pharmacological testing, these compounds appear useful as potential antipsychotic agents which lack the typical movement disorder side-effects of standard antipsychotic agents.
    Type: Grant
    Filed: December 18, 1984
    Date of Patent: August 12, 1986
    Assignee: Bristol-Myers Company
    Inventors: Joseph P. Yevich, Walter G. Lobeck, Jr.
  • Patent number: 4590196
    Abstract: A series of non-opiate analgesics of Formula I ##STR1## wherein R.sup.1 is hydrogen, alkyl, aralkyl, or aryloxyalkyl; R.sup.2 is alkyl or hydrogen; and R.sup.3 and R.sup.4 are independently selected from hydrogen, alkyl, acyloxy, alkoxy, alkylthio, halogen, hydroxyl, or trifluoromethyl; or a pharmaceutically acceptable acid addition salt.
    Type: Grant
    Filed: August 23, 1984
    Date of Patent: May 20, 1986
    Assignee: Bristol-Myers Company
    Inventors: David W. Smith, Joseph P. Yevich
  • Patent number: 4524206
    Abstract: Disubstituted N,N'-piperazinyl derivatives are disclosed wherein one substituent is heteroaryl and the other is alkylene attached to the ring nitrogen of substituted 2,5-pyrrolidinedion-1-yl moieties. The substitution pattern of the pyrrolidinedione ring involves either geminal disubstitution, including spiro ring fusion, or 3,4-phenyl ring fusion to give phthalimide derivatives. Heteroaryl substitution on the other piperazine nitrogen comprises pyridine, pyrimidine, and benzisothiazole ring systems. Representative examples of these compounds demonstrate useful central nervous system effects.
    Type: Grant
    Filed: September 12, 1983
    Date of Patent: June 18, 1985
    Assignee: Mead Johnson & Company
    Inventors: James S. New, Joseph P. Yevich
  • Patent number: 4491587
    Abstract: 6-(1H-Tetrazol-5-yl)thiazolo[3,2-a]pyrimidin-5-ones, 3-(1H-tetrazol-5-yl)-4H-pyrimido[2,1-b]benzothiazol-4-ones, and the corresponding imidazo- and triazolo- pyrimidines, thiones, and imines are useful as antiallergy and antiasthmatic compounds by virtue of their inhibitory action on the immediate hypersensitivity reaction in mammals and relaxant action on the tracheal muscle. Intermediates in the synthesis of these substances from 2-aminoazoles and ethoxymethylene malononitrile also have smooth muscle relaxant and immediate hypersensitivity reaction inhibitory activity.
    Type: Grant
    Filed: July 11, 1980
    Date of Patent: January 1, 1985
    Assignee: Mead Johnson & Company
    Inventors: Robert R. Covington, Davis L. Temple, Jr., Joseph P. Yevich
  • Patent number: 4452799
    Abstract: Disubstituted N,N-piperazinyl derivatives are disclosed wherein one substituent is benzisothiazol-3-yl or benzisoxazol-3-yl and the other is alkylene attached to heterocycles such as azaspiro[4.5]decanedione, dialkylglutarimide, thiazolidinedione and spirocyclopentylthiazolidinedione or butyrophenone-like groups. The compounds have psychotropic properties and 8-[4-[4-(1,2-benzisothiazol-3-yl)-1-piperazinyl]butyl]-8-azaspiro[4.5]deca ne-7,9-dione is a typical embodiment having selective antipsychotic activity.
    Type: Grant
    Filed: August 5, 1983
    Date of Patent: June 5, 1984
    Assignee: Mead Johnson & Company
    Inventors: Davis L. Temple, Jr., Joseph P. Yevich